Abbott Laboratories ( ABT +1.49%) more or less met analyst estimates in its first quarter, the results of which were ...

By Siddhi Mahatole and Puyaan Singh April 16 (Reuters) - Abbott cut its annual profit forecast on Thursday due to an impact ...

Abbott Laboratories continues to grapple with falling sales in its nutrition segment.

Abbott Laboratories stock has been punished hard in 2026, and the question is whether that punishment has overshot the ...

By Diana Novak Jones CHICAGO, April 10 (Reuters) - A jury in Chicago on Friday said Abbott Laboratories must pay $70 million ...

On April 20, Matt Miksic of Barclays lowered the firm’s price recommendation on ABT to $143 from $144. It reiterated an ...

Abbott beats Q1 earnings but trims guidance after $21B Exact Sciences acquisition. Medical devices grow 8.5% while nutrition ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott made one of the biggest deals in recent medtech history last week when it announced its plan to acquire Exact Sciences — maker of colon cancer screening test Cologuard — for $23 billion.

Most of what we do, from incubators to ventilators, simply buys time and treats complications while premature infants grow.